Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure

Nature Medicine

Volumn 5, Issue 10, 1999, Pages 1135-1142

  Heymans, S ^a   Luttun, A ^a   Nuyens, D ^a   Theilmeier, G ^a   Creemers, E ⁱ   Moons, L ^a   Dyspersin, G D ^b   Cleutjens, J P M ⁱ   Shipley, M ^c   Angellilo, A ^a   Levi, M ^a   Nube O ^d   Baker, A ^e   Keshet, E ^f   Lupu, F ^g   Herbert, J M ^h   Smits, J F M ⁱ   Shapiro, S D ^c   Baes, M ^a   Borgers, M ^b   Collen, D ^a   Daemen, M J A P ⁱ   Carmeliet, P ^a   more..

^a Institute for Biotechnology   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^g THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^h SANOFI   (France)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ELASTASE; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; STROMELYSIN; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE INACTIVATION; GENE TRANSFER; HEART ARRHYTHMIA; HEART CONDUCTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART RUPTURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCAR FORMATION;

ANIMALS; ARRHYTHMIA; BONE MARROW TRANSPLANTATION; CARDIAC OUTPUT, LOW; CELL MOVEMENT; COLLAGENASES; GENE TRANSFER TECHNIQUES; HEART RUPTURE; LEUKOCYTES; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; MICE, MUTANT STRAINS; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; PROTEASE INHIBITORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0032826035     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/13459     Document Type: Article

References (39)

1. Reddy, S.G. & Roberts, W.C. Frequency of rupture of the left ventricular free wall or ventricular septum among necropsy cases of fatal acute myocardial infarction since introduction of coronary care units. Am. J. Cardiol. 63, 906-911 (1989).
2. Varbella, F. et al. Subacute left ventricular free-wall rupture in early course of acute myocardial infarction. Clinical report of two cases and review of the literature. G. Ital. Cardiol. 29, 163-170 (1999).
3. Dalrympte-Hay, M.J., Monro, J.L., Livesey, S.A. & Lamb, R.K. Postinfarction ventricular septal rupture: the Wessex experience. Semin. Thorac. Cardiovasc. Surg. 10, 111-116 (1998).
4. Zahger, D. et al. Left ventricular free wall rupture as the presenting manifestation of acute myocardial infarction in diabetic patients. Am. J. Cardiol. 78, 681-682 (1996).
5. Peuhkurinen, K., Risteli, L., Jounela, A. & Risteli, J. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Am. Heart J. 131, 7-13 (1996).
6. Knoepfler, P.S., Bloor, C.M. & Carroll, S.M. Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion. J. Mol. Cell Cardiol. 27, 1317-1324 (1995).
7. Rohde, L.E. et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99, 3063-3070 (1999).
8. Robert, V. et al. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest. 76, 729-738 (1997).
9. Tyagi, S.C., Kumar, S., Cassatt, S. & Parker, J.L. Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion. Can. J. Physiol. Pharmacol. 74, 983-995 (1996).
10. Frangogiannis, N.G. et al. Cytokines and the microcirculation in ischemia and reperfusion. J. Mol. Cell Cardiol. 30, 2567-2576 (1998).
11. Carmeliet, P. et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genet. 17, 439-444 (1997).
12. Carmeliet, P. et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96, 3180-3191 (1997).
13. George, S.J., Johnson, J.L., Angelini, G.D., Newby, A.C. & Baker, A.H. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum. Gene Ther. 9, 867-877 (1998).
14. Alcorn, J.L. et al. Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene. Mol. Endocrinol. 7, 1072-1085 (1993).
15. Everts, V., van der Zee, E., Creemers, L. & Beertsen, W. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem. J. 28, 229-245 (1996).
16. Nunes, I. et al. Structure and activation of the large latent transforming growth factor-beta complex. Int. J. Obes. Relat. Metab. Disord. 20 Suppl 3, S4-8 (1996).
17. Severs, N.J. Pathophysiology of gap junctions in heart disease. J. Cardiovasc. Electrophysiol. 5, 462-475 (1994).
18. Carmeliet, P. et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation, and tumor angiogenesis. Nature 394, 485-490 (1998).
19. Vandeplassche, G., Hermans, C., Thone, F. & Borgers, M. Stunned myocardium has increased mitochondrial NADH oxidase and ATPase activities. Cardioscience 2, 47-53 (1991).
20. Feldhaus, L.M. & Liedtke, A.J. mRNA expression of glycolytic enzymes and glucose transporter proteins in ischemic myocardium with and without reperfusion. J. Mol. Cell Cardiol. 30, 2475-2485 (1998).
21. Przyklenk, K., Connelly, C.M., McLaughlin, R.J., Kloner, R.A. & Apstein, C.S. Effect of myocyte necrosis on strength, strain, and stiffness of isolated myocardial strips. Am. Heart J. 114, 1349-1359 (1987).
22. Schaffer, C.J. & Nanney, L.B. Cell biology of wound healing. Int. Rev. Cytol. 169, 151-181 (1996).
23. Koyama, H., Raines, E.W., Bornfeldt, K.E., Roberts, J.M. & Ross, R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87, 1069-1078 (1996).
24. Plesner, T., Behrendt, N. & Ploug, M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15, 398-408(1997).
25. Kleiner, D.E. & Stetler-Stevenson, W.G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol. 43, S42-51 (1999).
26. Chapman, H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Cur. Opin. Cell Biol. 9, 714-724 (1997).
27. Carmeliet, P. et al. Receptor-independent role of urokinase-type plasminogen activator in arterial wound healing and intima formation in mice. J. Cell Biol. 140, 233-245 (1998).
28. Rifkin, D.B., Mazzieri, R., Munger, J.S., Noguera, I. & Sung, J. Proteolytic control of growth factor availability. APMIS 107, 80-85 (1999).
29. Borregaard, N. & Cowland, J.B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89, 3503-3521 (1997).
30. Lee, J.K. et al. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nature Med. 4, 1383-1391 (1998).
31. Zhang, B. et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99, 1788-1794 (1999).
32. Lijnen, H.R. & Collen, D. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding and thrombosis. Fibrinolysis 3, 67-77 (1989).
33. Hamsten, A. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2, 3-9 (1987).
34. Henry, M. et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas cohort. Arterioscler. Thromb. Vasc. Biol. 18, 84-91 (1998).
35. Carmeliet, P. & Collen, D. Vascular development and disorders: molecular analysis and pathogenetic insights. Kidney Int. 53, 1519-1549 (1998).
36. Carmeliet, P. & Collen, D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase, and coagulation system. Thromb. Res. 91, 255-285 (1998).
37. Lutgens, E. et al. Chronic myocardial infarction in mice: cardiac structural and functional changes. Cardiovasc. Res. 41, 586-593 (1999).
38. Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nature Med. 5, 495-502 (1999).
39. Linton, M.F., Atkinson, J.B. & Fazio, S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 267, 1034-1037 (1995).